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Netherlands from a societal perspective. Methods: Health care, patient and fam-
ily and other use of resources for five different categories of side-effects were 
measured by means of a questionnaire. Respondents were patients with epilepsy 
who experienced at least one side-effect due to antiepileptic treatment in the 
last 12 months. Results: Based on data from 203 chronic epilepsy patients, the 
overall societal costs of common side-effects in 2012 are estimated to be € 20,751 
(CI: 15,049-27,196) per patient per year in the base case analysis. These societal 
costs exist of: mean health care costs (€ 4,458), mean patient and family costs (i.e. 
informal care and out of pocket expenses) (€ 10,526) and mean other costs (i.e. pro-
ductivity and daily routine losses) (€ 5,761). Examining the different categories of 
side-effects separately, ranging from the most to the least expensive category, the 
cost estimates were as follows: other side-effects (€ 13,228), behavioral side-effects 
(€ 9,689), general health side-effects (€ 7,454), cognitive side-effects (€ 7,285) and 
cosmetic side-effects (€ 2,845) per patient per year. Subgroup analyses showed sig-
nificant differences in costs between patients using monotherapy and those using 
polytherapy when looking at cognitive and cosmetic side-effects. ConClusions: 
These estimates should be considered in the overall assessment of the economic 
impact of a pharmacotherapy.
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aNalysis witH tHe QuebeC ProviNCial Drug reimbursemeNt Program 
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objeCtives: To assess resource utilization before and after the development of 
Alzheimer’s disease (AD), using the Quebec provincial drug reimbursement program 
database (RAMQ). Methods: This study included patients covered by the RAMQ 
who had at least one diagnosis of AD (ICD-9 code 3310) or have received at least 
one script for an AD medication (donepezil, rivastigmine, galantamine or meman-
tine) from January, 1985 to December, 2011. A control group of patients without AD 
was created on a 1:1 ratio and matched for age, gender and geographic location. 
The index date was defined as the date of the first AD diagnosis or the first script 
for AD medication whichever comes first. Health care resource costs were ana-
lyzed in terms of emergency room, outpatient clinic, intensive care unit and physi-
cian’s visits, hospitalizations and long-term care, plus AD medications and other 
medications costs. Annual health care costs were reported for the 5-years before 
and the 5-years after the index date. Results: Data were obtained for a random 
sample of 34,086 AD patients (mean age of 78.5 years [SD= 8.0], 65.2% females). 
Before the index date, health care costs were similar between AD patients and the 
control group, except for the year preceding AD. Indeed, cost per patient for this 
year increased from CDN$5,126 to CDN$8,839 for the AD group and from CDN$4,466 
to CDN$5,212 for the control group (72.4% vs. 16.7% increase respectively). For the 
5-year period after the index date, costs were significantly higher for AD patients 
with an average cost per patient per year of CDN$9,364 vs. CDN$5,864 for the control 
group (mean difference of CDN$3,500,p< 0.001). ConClusions: AD significantly 
increases health care resource costs, including medical resources and medications. 
Costs generated by AD patients cumulate over time leading to a major difference in 
long-term costs compared to non-AD patients.
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objeCtives: Parkinson Disease (PD) is the second commonest cause of neuro-
logical disability and affected approximately 5.2 million men and women world-
wide. Continuous subcutaneous apomorphine (CSAI) represents an alternative 
treatment option of advanced PD with motor fluctuation. The purpose of this 
analysis was to estimate the cost-effectiveness of CSAI compared with Levodopa/
carbidopa intestinal gel (LCIG), Deep-Brain-Stimulation (DBS) and Standard-of-care 
(SOC). Methods: We developed a multicounty Markov-Model to simulate the long-
term consequences, disease progression (Hoehn&Yahr-stages 3-5, percentage of 
waking-time in the OFF-state), complications and adverse-events. Complications 
are different for the alternatives (e.g. pump problems in case of LCIG, temporary/
permanent complications in case of DBS). We include moderate and severe adverse-
events and death. Monte-Carlo-simulation accounted for uncertainty. The model 
includes 25 health-states. Probabilities were derived from RCT and open-label stud-
ies; direct costs (2012) from published sources from the payer’s perspective (NHS and 
German health care systems). QALYs, life-years (LYs) and costs were projected over 
a life-time horizon and discounted according the national guidelines. Results: UK 
life-time costs associated with CSAI amounts to 70,258 £ and generates 2.85 QALYs 
and 6.28 LYs (106,530 € , 2.92 QALYs and 6.49 LYs for Germany). Costs associated 
with LCIG are 117,121 £, achieves 3.06 QALYs and 6.93 LYs (178,405 € , 3.18 QALYs and 
7.18 LYs for Germany). The incremental-cost per QALY gained (ICER) was 223,052 £ 
(281,089 € ). Costs for DBS are 88,361.61 £, associated with 2.75 QALYs and 6.38 LYs 
(121,988 € , 2.85 QALYs and 6.61 LYs for Germany). CSAI dominates DBS. SOC associ-
ated UK costs are 68,082.92 £; 2.62 QALYs and 5.76 LYs were reached (91,588 € , 2.7 
3QALYs and 6 LYs for Germany). ConClusions: CSAI is a cost-effective treatment 
alternative, reducing OFF-time and improving quality-of-life and is associated with 
a cost-advantage.
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were 178. The key cost driver for inpatients was daycare (hospitalization, medical 
and nursing care, therapies). ConClusions: The annual cost of treating patients 
with paraplegia in the private health care sector in Greece is high. This study is the 
first cost study in this disease area and additional studies should be undertaken in 
order to acquire a more complete picture of the cost of managing disease, in both 
the private and public health care sectors.
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objeCtives: PD-LID, a complication of L-Dopa treatment, is associated with inabil-
ity to perform daily living activities, reduction in quality of life and increase in 
health care costs. Limited data are currently available on the burden of this dis-
ease. LIDIA describes medical and non-medical resource utilization and economic 
impact of PD-LID patients from payer and society perspective according to LID 
severity: mild (mAIMS score< 8), moderate (mAIMS [8-12]) and severe (mAIMS> 12) 
patients. Methods: This observational, prospective, longitudinal, multicentre 6 
month-study was conducted by French neurologists specialized in Parkinson’s dis-
ease (PD). PD patients taking L-dopa for at least 3 years were included, with PD-LID 
present for more than 3 months and for more than 25% of the time. Results: 
Thirty-three neurologists included 186 patients (mean 68 years old, 52% women) 
with mean mAIMS score at 10. PD-LID patients were mainly followed by their neu-
rologists (96%) and general practitioner (GP) (84%) with more non-medical follow-up 
for severe patients. Almost 60% had at least one biological or radiological exami-
nation, only 31% required transport. All patients received L-Dopa (including 32% 
long-acting), and 69% dopaminergic agonists. Only 21% had at least one hospitali-
zation and over 40% needed home layout and mobility equipment. Most patients 
(70%) were assisted by a caregiver (24h/week), 43% required external assistance (6h/
week), 22% received an invalidity allowance. Total costs represent 35117€ , 33640€ and 
43739€ in respectively mild, moderate and severe patients (on average per patient/
year). Non-medical costs (transportations, paid external help, caregivers time, mobil-
ity equipment, home layout) are the major cost drivers (80%), including caregiver 
help (70%), followed by medical (consultations, treatments, hospitalizations)(15%) 
and indirect costs (allowances and work stoppages)(5%). ConClusions: The LIDIA 
study confirms that in this disabling disease, the economic burden is mainly sup-
ported by the patient family, with the payer part being 23%. Economic burden is 
greater in patients with severe dyskinesia.
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objeCtives: Herpes zoster (HZ) and its most common complication post-herpetic 
neuralgia (PHN: pain persisting months after the rash onset) are associated with 
substantial burden of disease. There is a sharp increase in incidence from the 
age of 50, impacting individuals, their relatives and society. The objective of our 
work was to conduct a critical review documenting the Humanistic, Economic and 
Societal Burden of HZ in Europe. Methods: Systematic searches were conducted in 
Medline, EMBASE, PSYCHINFO, EconLit, HEED and CRD databases, using a combina-
tion of search terms in title and abstracts. Articles, published from 2000 onwards, 
were selected for full review by two independent researchers in accordance with 
predefined eligibility criteria. Results: From a review of 1448 abstracts, 42 eligible 
articles, were identified which reported data concerning health care resource use 
(n= 26), direct costs (n= 21), indirect costs (n= 14), impact on health-related qual-
ity of life (HRQoL) (n= 21) and impact on caregivers (n= 3). Findings across studies 
highlight that levels of pain severity and the presence of PHN are associated with 
greater impairments in HRQoL and higher costs of management. At least 50% of 
employed patients missed work due to the disease. While the incidence of HZ and 
PHN increase with age, age was not a key driver of overall costs for HZ and PHN. 
Specifically, while direct costs (e.g. GP, specialists, medications, hospitalisations) 
tend to be higher for older patients, indirect costs (e.g. work time missed) are higher 
for younger patients. ConClusions: Available evidence highlights that HZ and 
PHN result in significant humanistic and economic burden for patients, health care 
systems and wider societies. There is a tendency to focus upon health care resource 
use and the direct costs of management which may result in an underestimation 
of the true burden of HZ and PHN, which is also expected to grow with the ageing 
European population.
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objeCtives: Epilepsy is a brain disorder which is characterized by recurrent 
unprovoked seizures. The outward effect of seizures can be as dramatic as a 
wild trashing movement or as mild as a brief loss of awareness. To reduce fre-
quency and severity of seizures, antiepileptic drugs are potentially an effective 
treatment for patients with epilepsy. However, side-effects are common. The 
negative consequences of side-effects can lead to treatment ranging from minor 
care to very expensive hospitalization. This cost analysis has been conducted 
to provide insight into the costs of side-effects due to antiepileptic drugs in The 
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in monotherapy and IFN+GA combined, it may be concluded that the first is a 
dominant strategy.
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Ryazhenov V.V., Emchenko I.V.
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objeCtives: To assess the cost-effectiveness of two conventional combinations 
of levodopa and decarboxylase inhibitors (benserazide or carbidopa) in the treat-
ment of Russian patients with Parkinson’s disease. Methods: The pharmaco-
economic model was developed based on the data from multicentre randomized 
controlled triple-blind trial (H. Pakkenberg et al., 1976) on the efficacy and toler-
ance of levodopa+benserazide and levodopa+carbidopa in the treatment of patients 
with Parkinson’s disease previously not treated with levodopa. A six-month time 
horizon was adopted in the model. The cost analysis included costs of the original 
preparation of levodopa+benserazide and costs of the available in Russia generic 
preparations of levodopa+carbidopa and considered on-demand antiemetic treat-
ment with domperidone to reduce the incidence of gastrointestinal side effects 
of levodopa. The efficacy of treatment was defined as proportion of patients 
with full compliance to the treatment protocol and proportion of patients with-
out side effects (nausea and vomiting, hyperkinesia). Results: Treatment with 
levodopa+benserazide was associated with significantly lower incidence of patient 
non-compliance (43% as compared to 76% in the levodopa+carbidopa group). Less 
patients in levodopa+benserazide group experienced side effects of levodopa. The 
expenses for antiemetic treatment was 8.7-fold lower in patients treated with 
levodopa+benserazide as compared to those received levodopa+carbidopa. Total 
costs in levodopa+benserazide group were 912,264.90 RUB per 100 patients and 
varied from 682,154.60 RUB to 1,255,226.00 RUB in levodopa+carbidopa groups. The 
cost-effectiveness ratios (CERs) were 15,692.02 RUB and 21,988.11 – 45,866.08 RUB per 
one patient with full compliance to the protocol in the levodopa+benserazide and 
levodopa+carbidopa groups, respectively. The similar results were observed for the 
CERs estimated per one patient without side effects of levodopa. ConClusions: 
The present study has demonstrated that administration of levodopa+benserazide 
is an economically effective strategy in the treatment of Russian patients with 
Parkinson’s disease.
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objeCtives: To evaluate the cost-effectiveness ratio of antiparkinsonian medica-
tion taken as monotherapy in patients with Parkinson’s disease (PD). Methods: 
A cost-effectiveness analysis (CEA) of therapies including pramipexole ER, prami-
pexole, ropinirole, piribedil and rasagiline has been performed. Direct medical costs 
including costs of medications and treatment of adverse drug effects for 1-year 
therapy of PD have been considered. The clinical effect of selected antiparkinsonian 
medication was assessed in percentage of patients responding to treatment, and 
also by means of the UPDRS II-III scale. All calculations were done in RUR prices 
of 2013 (nominal exchange rate RUR/USD = 30/1). Results: Pramipexole ER has 
the lowest cost-effectiveness ratio (CER) of RUR 57,572 per patient/year respond-
ing to antiparkinsonian therapy. Hence, pramipexole ER was the most effective 
antiparkinsonian preparation studied in pharmacoeconomic terms. Based on cost-
effectiveness ratio, the medications evaluated can be arranged in the following 
order: pramipexole ER (RUR 57,572), pramipexole (RUR 59,548), piribedil (RUR 70,921), 
ropinirole (RUR 71,887), and rasagiline (RUR 91,112). The model results were robust 
to deterministic sensitivity analysis with variable drug costs. Limitations: Absence 
of direct comparative evidence from randomized, double-blind, controlled studies 
makes interpretation of the data difficult. Only short-term studies (up to 24 months) 
were available and hence do not allow to evaluate the influence of pharmacotherapy 
on motor fluctuations as well as other longterm factors. ConClusions: The results 
of the present pharmacoeconomic analysis indicate that pramipexole ER is cost-
effective as first line therapy for the treatment of early stages of Parkinson’s disease 
from a Russian health care perspective. All five formulations evaluated, are well 
below the conditional “willingness to pay ratio” (equal to RUR 1,308607 in 2012). 
Hence, these preparations would qualify for application in the Russian system of 
public reimbursement.
PND32
Cost-effeCtiveNess aNalysis of laCosamiDe ComPareD witH 
staNDarD of aNtiePilePtiC Care baseD oN CliNiCal PraCtiCe Data
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objeCtives: To perform a cost-utility analysis of lacosamide as add-on therapy 
to standard antiepileptic drugs (AEDs) compared to standard AEDs alone based 
on individual patients data derived from actual clinical practice in the Czech 
Republic. Methods: Based on retrospective data collection of 409 patients with 
epilepsy treated with lacosamide for 6 months in actual clinical practice, we devel-
oped a cost-utility Markov cohort model. The model has 4 basic health states defined 
by number of seizures within 3 months plus 1 state represented by occurrence of 
severe side effects and 1 absorption state; death. Each health state was described 
by utility levels derived from literature. Transition probabilities for the first cycle 
were derived from observational study data and subsequently published literature. 
The model time-horizon was 20 years, 1 cycle length covered 3 months, and a 3% 
discount rate was used for costs and outcomes (Quality adjusted life years (QALYs)). 
Only costs attributed to drug acquisition were calculated, dosing of each AED was 
derived from the retrospective study. We performed probabilistic sensitivity analysis 
(PSA) with 3000 iterations using a willingness to pay (WTP) threshold equal to 3 
objeCtives: All recombinant human growth hormones (rhGH) have the same 
molecular structure, therefore providing equal efficacy and safety, and are granted 
the same reimbursement in the Czech Republic (CR). All rhGH are currently 
administered subcutaneously once a day, differing only in applicators. Easypod 
is the only applicator that enables monitoring the dose, time and date of each 
injection and allows feedback control by doctors. The objective was to assess the 
cost-effectiveness of monitored rhGH treatment administered by Easypod with 
an increase in reimbursement of 10% compared to the standard non-monitored 
rhGH administration in CR. Methods: The interim results (n= 596) of an ongo-
ing multicenter, non-comparative, observational, longitudinal study (ECOS) were 
used to populate deterministic cohort model. The model simulated long-term costs 
and benefits development of rhGH treatment. Evaluation was developed primar-
ily on evidence-based connection (from ECOS) between the monitoring of treat-
ment and patient adherence to the treatment. Increased adherence of monitored 
patients was transferred to the increased effectiveness of the treatment, based on 
published study. Model further transformed the long-term treatment benefits to 
the increased quality of life, using QALY as the target parameter using empirical 
transformation. Costs were expressed from the payer’s perspective. Results: Due 
to an increased adherence in monitored patients, the hypothetical cohort of 10,000 
boys generated 9,517 incremental QALY and CZK1.6 billion incremental costs in a 
lifetime horizon. A hypothetical cohort of 10,000 girls generated 11,504 incremental 
QALY and CZK1.35 billion incremental costs. The average cost per 1 QALY (ICER) is 
approximately CZK157,000 for the patient with GHD. ConClusions: Monitoring 
of the treatment may lead to an increased adherence and more effective treatment 
at relatively low cost, hence being considered cost-effective. Sensitivity analysis 
showed that ICER did not exceed CZK500,000 upon the considered uncertainty.
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objeCtives: Multiple sclerosis (MS) causes significant disability and diminished 
quality of life globally. BG-12 is a new oral treatment for relapsing forms of MS 
that is currently approved in the US and Canada and is under regulatory review in 
Europe. A cost-effectiveness model was developed to compare the health economic 
impact of BG-12 against other disease-modifying therapies (DMTs) as first-line 
treatment for relapsing-remitting MS (RRMS) from a Ministry of Health perspec-
tive in Canada. Methods: A cohort-based Markov model was developed to simu-
late patients’ progression through a series of health states, based on the Kurtzke 
Extended Disability Status Scale (EDSS) over a lime-time horizon. Patients entered 
the model based on a distribution of baseline EDSS scores, from which they could 
either progress/regress to higher/lower EDSS state, or remain in the same state. 
Relapses could occur at any EDSS score. Results from a mixed-treatment comparison 
were used to inform model inputs for disease progression and relapse rates per 
treatment. In addition to the overall discontinuation rates reported in trials, patients 
discontinued treatment on conversion to secondary-progressive MS or reaching 
EDSS 7. Costs included direct medical costs stratified by EDSS score, along with 
relapse, adverse events (AEs), and treatment-related costs. Utilities were accrued 
based on time spent in each EDSS state, adjusted for disutilities associated with 
AEs and caregiver burden. A 5% discount rate was applied. Results: Compared 
with glatiramer acetate, BG-12 yielded 0.396 incremental quality adjusted life years 
(QALYs) at an incremental cost of CAD22,437, resulting in an ICER of CAD56,649. 
Compared with Rebif 44µg, BG-12 resulted in an ICER of CAD10,669. Results were 
consistent across a wide range of one-way and probabilistic sensitivity analy-
ses. ConClusions: Based on traditional cost-effectiveness thresholds in Canada, 
BG-12 can be considered a cost-effective option compared to other first line DMTs.
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objeCtives: To assess the cost-effectiveness of the Disease Modifying Treatments 
(DMT), Glatiramer Acetate (GA) and Interferon beta-1a (IFN) in monotherapy alone 
and in combination for the prevention of relapses with established Relapsing–
Remitting Multiple Sclerosis (RRMS) among Spanish patients aged between 18 and 
60 years old. Methods: A Markov model was developed to represent the transition 
of a cohort of patients over a 10 year period using the perspective of the Spanish 
National Health Service (NHS). The model considered five different health states 
with one-year cycles including without relapse, patients with suspect, non-protocol 
defined and protocol defined exacerbations, as well as the category information lost. 
Efficacy data was obtained from the 3-year CombiRx Study. Costs were reported in 
2013 Euros and a 3%discount rate was applied for health and benefits. Deterministic 
results were presented as the annual treatment cost for the number of relapses. 
A probabilistic sensitivity analysis was performed to test the robustness of the 
model. Results: Deterministic results showed that the expected cost per patient 
was lower when treated with GA (€ 13,843) compared with IFN (€ 15,589) and the 
combined treatment with IFN+GA (€ 21,539). The number of relapses were lower in 
the GA cohort with 3.81 versus 4.08 in the IFN cohort and 4.18 in the cohort treated 
with IFN+GA. Results from probabilistic sensitivity analysis showed that GA has a 
higher probability of being cost-effective than the treatment with IFN or IFN+GA 
for threshold values from € 28,000 onwards, independent of the maximum that the 
Spanish NHS is willing to pay for avoiding relapses. ConClusions: GA showed 
to be a cost-effective treatment option for the prevention of relapses in Spanish 
patients diagnosed with RRMS. When GA in monotherapy is compared with INF 
